Tissue Repair Ltd (AU:TRP)
ASX:TRP
Want to see AU:TRP full AI Analyst Report?
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$6.35M
Enterprise Value-AU$1.64M
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt across 2022–2025 meaningfully lowers financial risk, reduces fixed interest burdens and gives management optionality to prioritize R&D or commercialization without immediate servicing pressure. Over a 2–6 month horizon this supports resilience and strategic flexibility.
Rapid Revenue AccelerationA sharp revenue increase into 2025 demonstrates accelerating commercial traction and a larger revenue base to build from. Durable top-line growth improves scalability prospects, helps absorb fixed costs, and strengthens the platform for further product commercialization and margin improvement over coming months.
High Gross Margins And Cash-aligned LossesVery high gross margins indicate efficient core economics, while free cash flow tracking net losses (FCF to net income ~1.0–1.1) shows reported losses are largely cash-based rather than driven by non-cash accounting. This alignment improves the predictability of cash recovery as revenues scale.
Bears Say
Persistent Negative Cash FlowConsistently negative operating and free cash flows, with FCF worsening ~24% in 2025, indicate rising cash burn and shrinking runway. Absent material margin or revenue acceleration, this elevates near-term financing needs and the likelihood of dilutive capital raises within a 2–6 month horizon.
Deep And Persistent Operating LossesSignificant negative EBIT and an approximately -161% net margin show the business remains loss-making despite revenue growth. Sustained operating losses imply prolonged investment without a clear profitability timeline, constraining free cash generation and reducing near-term return prospects.
Material Equity ErosionDeclining shareholders' equity over multiple years erodes the capital cushion available to absorb losses and increases sensitivity to funding shocks. Reduced equity heightens the probability of future equity issuance or dilution if negative cash flow persists, weakening long-term financial flexibility.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.10 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$6.35M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.036.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-29.91%
Trailing 12-Months
Asset Growth
-25.56%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Options Prices
Currently, No data available
---